Opdualag 240 mg/80 mg concentrate for solution for infusion
*Company:
Bristol-Myers Squibb Pharma EEIGStatus:
No Recent UpdateLegal Category:
Product subject to restricted prescription (C)Active Ingredient(s):
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company
Educational materials 'FOR HEALTHCARE PROFESSIONALS' (HCPs) are additional risk minimisation measures that are intended to promote the safe and effective use of the medicinal product.
(Click to Download) Opdualag (nivolumab and relatlimab) Patient Card
Risk Minimisation Materials
(Click to Download) Opdualag (nivolumab and relatlimab) Healthcare Professional (HCP) Letter
Risk Minimisation Materials
Bristol-Myers Squibb Pharma EEIG
Address:
Plaza 254, Blanchardstown Corporate Park 2, Dublin 15, D15 T867, IrelandMedical Information E-mail:
medical.information@bms.comTelephone:
+353 1 483 3625Medical Information Direct Line:
Freephone 1 800 749 749Stock Availability:
bmscustomer-service.chester@bms.com